Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Screening Blood Donations for Zika, Costly With Low Yields
From - Diagnostic Testing & Emerging Technologies
Screening the entire U.S. blood supply for Zika virus may not be worth the $42 million price tag. Fifteen months of screening all…
OIG Work Plan Monthly Review: May 2018
From - G2 Compliance Advisor
Of the seven new Work Plan items, none directly impact labs and lab services. However, one item on Medicare Part B reimbursement of outpatient cardiac and…
Medicaid Fraud: Enforcement Continues to Trend Down as Labs Drift Deeper into the Background
From - National Intelligence Report
Last month, the OIG published its annual summary of Medicaid Fraud Control Unit (MCFU) activity for FY 2017. Here is a summary of the key findings, trends and…
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
From - Laboratory Industry Report
While M&A activity in the wider healthcare industry is heating up deal making in the diagnostics space remains relatively light, not so much in terms of volume but…
New FDA Guidance Aims to Ease Approval for New NGS Tests—But It Probably Won’t Work
From - National Intelligence Report
Test makers have long complained about the FDA's unwillingness to embrace technology and diagnostics advances. But on April 13, the agency took steps to address…
Genetic Risk Score Could Improve Diagnosis of Atrial Fibrillation
From - Diagnostic Testing & Emerging Technologies
A genetic risk score (GRS) may identify patients at highest risk for developing atrial fibrillation (AF), according to a study published…
The Dx Pipeline: A Roundup of the Month’s Key New Product Launches
From - Laboratory Industry Report
Fluidigm, Qiagen and MNG Laboratories launched multiple products. Here's a rundown of the key diagnostic product launches from late March through mid-April…